Literature DB >> 33333594

Factors associated with 30-day soft tissue complications following upper extremity sarcoma surgery.

Yannick A J Hoftiezer1, Jonathan Lans1, Brian B Freniere1, Kyle R Eberlin1, Neal C Chen1, Santiago A Lozano-Calderón1.   

Abstract

BACKGROUND AND OBJECTIVES: The incidence of soft tissue complications following sarcoma surgery in the upper extremity is reportedly high. Therefore, this study assessed the National Surgical Quality Improvement Program (NSQIP) database to identify independent risk factors, while also reporting the incidence of soft tissue complications in the first 30 days after surgery.
METHODS: A total of 620 patients that underwent surgical treatment for upper extremity sarcoma were included from the NSQIP database. Soft tissue complications were defined as surgical site infection, wound dehiscence, or soft-tissue related reoperations. Clinically relevant patient and treatment characteristics were selected and analyzed.
RESULTS: The 30-day soft tissue complication rate was 4.7%. In the multivariable analysis, higher body mass index (p = .047) and longer operative times (p = .002) were independently associated with soft tissue complications.
CONCLUSIONS: Higher body mass index and longer operative times are risk factors for soft tissue complications following upper extremity sarcoma surgery. The soft-tissue complication rate following resection of upper extremity tumors is low in this national cohort, possibly due to the relatively small tumor size and low prevalence of radiotherapy.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  orthopedic oncology; predictors; sarcoma; soft tissue complications; upper extremity

Year:  2020        PMID: 33333594     DOI: 10.1002/jso.26311

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  1 in total

1.  Nutritional Predictors of Wound Infection in Patients with Lower Extremity Soft Tissue Sarcoma.

Authors:  Adam Kline; Pramod Kamalapathy; Katharine Bruce; Kevin Raskin; Joseph Schwab; Santiago Lozano-Calderón
Journal:  Ann Surg Oncol       Date:  2021-05-12       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.